COMMUNIQUÉS West-GlobeNewswire
-
BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
03/02/2026 -
Socrates Health Solutions Announces Advances in Proprietary Non-Invasive Glucose Monitoring Technology; Shareholders Include NFL Players Association and OneTeam Partners
03/02/2026 -
RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy
03/02/2026 -
MediGlow Utility (MGU) Releases a Technical Exploration Framework for Digital Identity and Privacy Protection
03/02/2026 -
Berry Street Named to 2026 New York Digital Health 100 List
03/02/2026 -
Novo Nordisk releases 2026 sales and operating profit outlook
03/02/2026 -
Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025
03/02/2026 -
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
03/02/2026 -
Byonyks X1: Revolutionizing Dialysis - Now FDA Cleared and Planning to start Patients in the U.S.
03/02/2026 -
Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems
03/02/2026 -
AdhereHealth Announces Appointment of CEO Kempton Presley and President & COO Patrick McNulty as Members of the Board of Directors
03/02/2026 -
Mapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026
03/02/2026 -
HFMA’s Vitalic Health to gather more than 50 payers, providers and tech leaders to address rising claim denials
03/02/2026 -
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
03/02/2026 -
Byonyks X1: Revolutinizing Dialysis - Now FDA Cleared and Planning to start Patients in the U.S.
03/02/2026 -
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
03/02/2026 -
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
03/02/2026 -
Adam Ferrari Announces 2026 Health Science Scholarship to Support Students Dedicated to Caring for Patients with Physical Disabilities
03/02/2026 -
Beghou Names Meredith Ressi as President and Chief Growth Officer
03/02/2026
Pages